The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts
Aim: We sought to determine the safety profile of a therapeutic candidate composed of the released molecules from a combination of human adipose-derived mesenchymal stem cells and fibroblasts. Although stem cells, their progenitor cells and the molecules that are released from these cells have some...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-08-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2020-0027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153125854314496 |
|---|---|
| author | Greg Maguire Peter Friedman |
| author_facet | Greg Maguire Peter Friedman |
| author_sort | Greg Maguire |
| collection | DOAJ |
| description | Aim: We sought to determine the safety profile of a therapeutic candidate composed of the released molecules from a combination of human adipose-derived mesenchymal stem cells and fibroblasts. Although stem cells, their progenitor cells and the molecules that are released from these cells have some demonstrated therapeutic value, much more needs to learn about the efficacy, mechanism of action and the safety profiles of these stem cell-based therapeutics. Methods: A number of cellular, in vitro, in vivo and human studies were performed to analyze cellular, tissue and systemic safety profiles of the combinatorial product. Results: At the levels tested in this study, ranging from demonstrated therapeutic doses to supratherapeutic doses, the combinatorial product demonstrated an excellent safety profile in all in vitro, cellular, tissue and systemic studies. Conclusions: We found evidence that a therapeutic candidate composed of the molecules released from human adipose-derived mesenchymal stem cells and human fibroblasts has an excellent safety profile, and that the product warrants further studies for safety and efficacy where dosing may include topical application, injection and oral application. |
| format | Article |
| id | doaj-art-a509d3c1bf31430aaf8ca1bfd03140a4 |
| institution | OA Journals |
| issn | 2056-5623 |
| language | English |
| publishDate | 2020-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-a509d3c1bf31430aaf8ca1bfd03140a42025-08-20T02:25:48ZengTaylor & Francis GroupFuture Science OA2056-56232020-08-016710.2144/fsoa-2020-0027The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblastsGreg Maguire0Peter Friedman11Bio Regenerative Sciences, Inc. San Diego, CA 92121, USA1Bio Regenerative Sciences, Inc. San Diego, CA 92121, USAAim: We sought to determine the safety profile of a therapeutic candidate composed of the released molecules from a combination of human adipose-derived mesenchymal stem cells and fibroblasts. Although stem cells, their progenitor cells and the molecules that are released from these cells have some demonstrated therapeutic value, much more needs to learn about the efficacy, mechanism of action and the safety profiles of these stem cell-based therapeutics. Methods: A number of cellular, in vitro, in vivo and human studies were performed to analyze cellular, tissue and systemic safety profiles of the combinatorial product. Results: At the levels tested in this study, ranging from demonstrated therapeutic doses to supratherapeutic doses, the combinatorial product demonstrated an excellent safety profile in all in vitro, cellular, tissue and systemic studies. Conclusions: We found evidence that a therapeutic candidate composed of the molecules released from human adipose-derived mesenchymal stem cells and human fibroblasts has an excellent safety profile, and that the product warrants further studies for safety and efficacy where dosing may include topical application, injection and oral application.https://www.future-science.com/doi/10.2144/fsoa-2020-0027inflammationstem cellsstem cell safetystem cell secretometoxicitytumorigenesis |
| spellingShingle | Greg Maguire Peter Friedman The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts Future Science OA inflammation stem cells stem cell safety stem cell secretome toxicity tumorigenesis |
| title | The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| title_full | The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| title_fullStr | The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| title_full_unstemmed | The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| title_short | The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| title_sort | safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts |
| topic | inflammation stem cells stem cell safety stem cell secretome toxicity tumorigenesis |
| url | https://www.future-science.com/doi/10.2144/fsoa-2020-0027 |
| work_keys_str_mv | AT gregmaguire thesafetyofatherapeuticproductcomposedofacombinationofstemcellreleasedmoleculesfromadiposemesenchymalstemcellsandfibroblasts AT peterfriedman thesafetyofatherapeuticproductcomposedofacombinationofstemcellreleasedmoleculesfromadiposemesenchymalstemcellsandfibroblasts AT gregmaguire safetyofatherapeuticproductcomposedofacombinationofstemcellreleasedmoleculesfromadiposemesenchymalstemcellsandfibroblasts AT peterfriedman safetyofatherapeuticproductcomposedofacombinationofstemcellreleasedmoleculesfromadiposemesenchymalstemcellsandfibroblasts |